Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bjps.2024.07.051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
J Pharm Policy Pract
December 2024
Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Background: High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.
View Article and Find Full Text PDFUnderstanding the complex function of gut microbiota: its impact on the pathogenesis of obesity and beyond: a comprehensive review.
Diabetol Metab Syndr
December 2024
Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Obesity is a multifactorial condition influenced by genetic, environmental, and microbiome-related factors. The gut microbiome plays a vital role in maintaining intestinal health, increasing mucus creation, helping the intestinal epithelium mend, and regulating short-chain fatty acid (SCFA) production. These tasks are vital for managing metabolism and maintaining energy balance.
View Article and Find Full Text PDFPharmacological management of pediatric metabolic dysfunction-associated steatotic liver disease.
J Pediatr Gastroenterol Nutr
January 2025
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Pediatric obesity, characterized by a body mass index (BMI) at or above the 95th percentile for age, affects a substantial number of children and adolescents worldwide. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, represents a prominent hepatic manifestation of obesity and metabolic syndrome, emerging as the most prevalent hepatic disorder among pediatric patients and a significant contributor to liver transplantation in adults. The escalating prevalence of pediatric MASLD mirrors the alarming rise in childhood obesity rates over recent decades.
View Article and Find Full Text PDFExploring omics signature in the cardiovascular response to semaglutide: Mechanistic insights and clinical implications.
Eur J Clin Invest
February 2025
Department of Medical Sciences, Institute of Biomedicine iBiMED, University of Aveiro, Aveiro, Portugal.
Article Synopsis
- Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes, showing significant heart health benefits.
- The review explores how advanced techniques like mass spectrometry and NMR can reveal molecular changes related to insulin, weight management, and heart health linked to semaglutide, while also noting current research challenges.
- The future potential of combining proteomic and metabolomic data with AI could enhance the prediction of cardiovascular outcomes, leading to better management for patients with type 2 diabetes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!